Published : Sept. 8, 2016 - 15:46
[
THE INVESTOR]
Komipharm, a veterinary pharmaceutical company, announced on Sept. 7 that its PAX-1, trade name Kominox, has been granted permission for sale in Australia, in response to Korea Exchange’s inquiry regarding the company’s stock price surge.
Kominox is a nonopioid painkiller that also fights cancer and Australian Therapeutic Goods Administration has approved use of the medicine to treat progressive cancer patients with chronic pains through all stages, the company added.
By Hwang You-mee (
glamazon@heraldcorp.com)